Literature DB >> 24173188

Chronic graft-versus-host disease: clinical presentation of multiple lesions of lichenoid and atrophic pattern.

Luiza Vasconcelos1, Erica Cristina Vieira, Eliana Maria Minicucci, Ana Gabriela Salvio, Mair Pedro de Souza, Mariangela Esther Alencar Marques, Silvio Alencar Marques.   

Abstract

Graft-versus-host disease is observed mainly in recipients of hematopoietic cell transplantation and is expressed by cutaneous or systemic signals and symptoms. Graft-versus-host disease is clinically classified as acute or chronic. Chronic Graft-versus-host disease occurs in up to 70% of hematopoietic cell transplanted patients and its clinical manifestations have important impact on morbidity and quality of life. The authors report an expressive cutaneous, oral and adnexal involvement in a patient with chronic Graft-versus-host disease with multiple lesions of lichenoid and atrophic pattern.

Entities:  

Mesh:

Year:  2013        PMID: 24173188      PMCID: PMC3798359          DOI: 10.1590/abd1806-4841.20132128

Source DB:  PubMed          Journal:  An Bras Dermatol        ISSN: 0365-0596            Impact factor:   1.896


  9 in total

1.  Graft-versus-host disease: part II. Management of cutaneous graft-versus-host disease.

Authors:  Sharon R Hymes; Amin M Alousi; Edward W Cowen
Journal:  J Am Acad Dermatol       Date:  2012-04       Impact factor: 11.527

2.  Graft-versus-host disease: part I. Pathogenesis and clinical manifestations of graft-versus-host disease.

Authors:  Sharon R Hymes; Amin M Alousi; Edward W Cowen
Journal:  J Am Acad Dermatol       Date:  2012-04       Impact factor: 11.527

3.  Medium dose long-wavelength ultraviolet A (UVA1) phototherapy for the treatment of acute and chronic graft-versus-host disease of the skin.

Authors:  T Wetzig; M Sticherling; J-C Simon; U Hegenbart; D Niederwieser; H K Al-Ali
Journal:  Bone Marrow Transplant       Date:  2005-03       Impact factor: 5.483

4.  National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report.

Authors:  Alexandra H Filipovich; Daniel Weisdorf; Steven Pavletic; Gerard Socie; John R Wingard; Stephanie J Lee; Paul Martin; Jason Chien; Donna Przepiorka; Daniel Couriel; Edward W Cowen; Patricia Dinndorf; Ann Farrell; Robert Hartzman; Jean Henslee-Downey; David Jacobsohn; George McDonald; Barbara Mittleman; J Douglas Rizzo; Michael Robinson; Mark Schubert; Kirk Schultz; Howard Shulman; Maria Turner; Georgia Vogelsang; Mary E D Flowers
Journal:  Biol Blood Marrow Transplant       Date:  2005-12       Impact factor: 5.742

5.  Comparative analysis of risk factors for acute graft-versus-host disease and for chronic graft-versus-host disease according to National Institutes of Health consensus criteria.

Authors:  Mary E D Flowers; Yoshihiro Inamoto; Paul A Carpenter; Stephanie J Lee; Hans-Peter Kiem; Effie W Petersdorf; Shalini E Pereira; Richard A Nash; Marco Mielcarek; Matthew L Fero; Edus H Warren; Jean E Sanders; Rainer F Storb; Frederick R Appelbaum; Barry E Storer; Paul J Martin
Journal:  Blood       Date:  2011-01-24       Impact factor: 22.113

Review 6.  Cutaneous manifestations of chronic graft-versus-host disease.

Authors:  Sharon R Hymes; Maria L Turner; Richard E Champlin; Daniel R Couriel
Journal:  Biol Blood Marrow Transplant       Date:  2006-11       Impact factor: 5.742

Review 7.  Graft-versus-host disease.

Authors:  James L M Ferrara; John E Levine; Pavan Reddy; Ernst Holler
Journal:  Lancet       Date:  2009-03-11       Impact factor: 79.321

8.  Narrowband UV-B phototherapy in the treatment of cutaneous graft versus host disease.

Authors:  Marcella Grundmann-Kollmann; Hans Martin; Ralf Ludwig; Stefan Klein; Wolf-Henning Boehncke; Dieter Hoelzer; Roland Kaufmann; Maurizio Podda
Journal:  Transplantation       Date:  2002-12-15       Impact factor: 4.939

9.  Nonmelanoma skin and mucosal cancers after hematopoietic cell transplantation.

Authors:  Wendy Leisenring; Debra L Friedman; Mary E D Flowers; Jeffrey L Schwartz; H Joachim Deeg
Journal:  J Clin Oncol       Date:  2006-02-06       Impact factor: 44.544

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.